Thursday January 24, 2019 20:12

Heathcare Press Release : 26 Apr 2017

Britannia Pharmaceuticals: Landmark Apomorphine Study Confirms its Established Role as a Highly Heathcare—26 Apr 17

Results from the first randomized, controlled trial investigating the efficacy and safety of APO-go(R)/MOVAPO(R) (apomorphine) subcutaneous infusion in Parkinson's disease (PD) patients whose motor symptoms are not controlled by other therapies - the